Omeros 将来の成長

Future 基準チェック /26

Omerosは、39.1%と68.8%でそれぞれ年率39.1%で利益と収益が成長すると予測される一方、EPSはgrowで44.8%年率。

主要情報

39.1%

収益成長率

44.8%

EPS成長率

Pharmaceuticals 収益成長	21.3%
収益成長率	68.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:3O8 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	26	-126	N/A	N/A	2
12/31/2025	8	-147	N/A	N/A	2
12/31/2024	N/A	-170	N/A	N/A	2
9/30/2024	N/A	-185	-155	-155	N/A
6/30/2024	N/A	-200	-156	-155	N/A
3/31/2024	N/A	-179	-142	-142	N/A
12/31/2023	N/A	-175	74	75	N/A
9/30/2023	N/A	-182	84	84	N/A
6/30/2023	N/A	-185	90	90	N/A
3/31/2023	N/A	-182	103	103	N/A
12/31/2022	N/A	-182	-87	-86	N/A
9/30/2022	N/A	-183	-79	-79	N/A
6/30/2022	N/A	-173	-77	-77	N/A
3/31/2022	N/A	-181	-85	-85	N/A
12/31/2021	N/A	-192	-110	-110	N/A
9/30/2021	-63	-217	-110	-110	N/A
6/30/2021	-37	-211	-121	-121	N/A
3/31/2021	-24	-194	-131	-131	N/A
12/31/2020	N/A	-173	-100	-100	N/A
9/30/2020	97	-130	-105	-105	N/A
6/30/2020	100	-108	-78	-77	N/A
3/31/2020	114	-89	-56	-56	N/A
12/31/2019	N/A	-147	-60	-60	N/A
9/30/2019	100	-79	-62	-62	N/A
6/30/2019	75	-102	-92	-91	N/A
3/31/2019	50	-121	-106	-105	N/A
12/31/2018	30	-127	-104	-104	N/A
9/30/2018	22	-120	-84	-83	N/A
6/30/2018	39	-88	N/A	-58	N/A
3/31/2018	54	-68	N/A	-35	N/A
12/31/2017	65	-53	N/A	-36	N/A
9/30/2017	64	-57	N/A	-43	N/A
6/30/2017	54	-63	N/A	-43	N/A
3/31/2017	46	-61	N/A	-48	N/A
12/31/2016	42	-67	N/A	-52	N/A
9/30/2016	35	-67	N/A	-57	N/A
6/30/2016	27	-73	N/A	-61	N/A
3/31/2016	21	-77	N/A	-64	N/A
12/31/2015	14	-75	N/A	-65	N/A
9/30/2015	7	-76	N/A	-64	N/A
6/30/2015	4	-74	N/A	-66	N/A
3/31/2015	1	-76	N/A	-64	N/A
12/31/2014	1	-74	N/A	-58	N/A
9/30/2014	1	-55	N/A	-43	N/A
6/30/2014	1	-50	N/A	-38	N/A
3/31/2014	1	-46	N/A	-32	N/A
12/31/2013	2	-40	N/A	-30	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 3O8今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 3O8今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 3O8今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 3O8の収益 ( 68.8% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 3O8の収益 ( 68.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 3O8の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Omeros 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

New major risk - Financial position

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

No longer forecast to breakeven

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.61 loss in 2Q 2020)

Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentation at 2021 Annual Congress of the European Hematology Association

Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906

Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab

Omeros Corporation Announces Extension of U.S. Food and Drug Administration Review Period for Narsoplimab in HSCT-TMA

Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ Pivotal Trial of Narsoplimab for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.54 loss in 1Q 2020)

Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration

Full year 2020 earnings released: US$2.42 loss per share (vs US$1.71 loss in FY 2019)

Revenue misses expectations

Omeros Corporation to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: €18.15

Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer

New 90-day high: €16.20

Omeros Corporation Announces Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA

New 90-day high: €12.40

Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm Separate Payment for Omeros’ FDA-Approve OMIDRIA in Ambulatory Surgery Centers

New 90-day high: €11.37

Omeros Corporation Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

Third quarter 2020 earnings released: US$0.66 loss per share

Revenue beats expectations

Omeros Corporation to Report Q3, 2020 Results on Nov 09, 2020

Omeros Corporation to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA

New 90-day low: €8.04

Omeros Corporation has completed a Follow-on Equity Offering in the amount of $100.05 million.

First half earnings released

New 90-day low - €11.27

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘